N5334 Final exam with verified answers
Prescribing ,,basics ,,- ,,ANSWER: ,, ,,➡ ,,Prescribing ,,is ,,regulated ,,by ,,state ,,BON
Proper ,,RX ,,- ,,ANSWER: ,, ,,➡ ,,Providers ,,name ,,and ,,address, ,,Telephone
DEA
Pt ,,name/DOB/Addres
Name ,,of ,,Drug, ,,strength, ,,SIG(directions) ,,with ,,indication/Route ,,and ,,frequency, ,,Quantity ,,and ,,signature.
Drug ,,Schedules: ,,Most ,,addictive ,,to ,,least ,,- ,,ANSWER: ,, ,,➡ ,,1: ,,Heroin,LSD, ,,MJ
2: ,,hydrocodone, ,,cocaine, ,,Methamphetamine, ,,methadone, ,,oxycodone, ,,meperidine, ,,fentanyl, ,,adderall,
,,ritalin
3: ,,codeine, ,,ketamine, ,,testosterone
4: ,,xanax, ,,valium, ,,soma, ,,ambient, ,,tramadol
5: ,,antidiarrheal, ,,antitussives, ,,lomotil, ,,lyrica
Pharmicodyamics ,,- ,,ANSWER: ,, ,,➡ ,,The ,,effects ,,of ,,drug ,,on ,,the ,,body. ,,Receptors ,,are ,,large ,,molecules
,,usually ,,proteins, ,,that ,,interact ,,and ,,mediate ,,the ,,action ,,of ,,drugs
agonist ,,- ,,ANSWER: ,, ,,➡ ,,produce ,,receptor ,,stimulation ,,and ,,a ,,conformational ,,change ,,every ,,time ,,they
,,bind. ,,Do ,,not ,,need ,,all ,,available ,,receptors ,,to ,,produce ,,a ,,maximum ,,response
Partial ,,agonist ,,- ,,ANSWER: ,, ,,➡ ,,drugs ,,that ,,have ,,properties ,,in ,,b/w ,,those ,,of ,,full ,,agonist ,,and ,,antagonist.
,,They ,,bind ,,to ,,receptors ,,but ,,when ,,they ,,occupy ,,the ,,receptor ,,sites, ,,they ,,stimulate ,,only ,,some ,,of ,,the
,,receptors.
antagonist ,,- ,,ANSWER: ,, ,,➡ ,,drugs ,,with ,,affinity ,,for ,,a ,,receptor ,,but ,,with ,,no ,,intrinsic ,,activity. ,,Affinity
,,allows ,,the ,,antagonist ,,to ,,bind ,,to ,,receptors, ,,but ,,lack ,,of ,,intrinsic ,,activity ,,prevents ,,the ,,bound
,,antagonist ,,from ,,causing ,,receptor ,,activation. ,,The ,,block ,,action ,,of ,,drugs ,,(ex. ,,Narcan)
,Bioavailabity ,,- ,,ANSWER: ,, ,,➡ ,,% ,,of ,,administered ,,dosage ,,of ,,the ,,drug ,,that ,,survives ,,the ,,first ,,pass
,,through ,,the ,,liver ,,and ,,reaches ,,the ,,blood ,,stream
half ,,life ,,- ,,ANSWER: ,, ,,➡ ,,Time ,,required ,,for ,,the ,,amount ,,of ,,a ,,drug ,,in ,,the ,,body ,,to ,,decline ,,by ,,50%, ,,drugs
,,with ,,shorter ,,half ,,lives ,,must ,,be ,,administer ,,frequently. ,,4.5-5.5 ,,times ,,the ,,half ,,life ,,to ,,get ,,steady ,,state
,,and ,,to ,,be ,,limited ,,from ,,the ,,body
what ,,the ,,body ,,does ,,to ,,the ,,drug ,,- ,,ANSWER: ,, ,,➡ ,,absorption, ,,distribution, ,,metabolism, ,,excretion
Distribution ,,- ,,ANSWER: ,, ,,➡ ,,movement ,,of ,,absorbed ,,drug ,,in ,,bodily ,,fluids ,,throughout ,,the ,,body ,,to
,,target ,,tissue. ,,Properties ,,affecting: ,,lipid/water ,,solubility, ,,PH ,,affects ,,ionization ,,of ,,drug, ,,protein ,,binding,
,,size ,,of ,,molecule ,,(smaller ,,molecules ,,are ,,more ,,able ,,to ,,diffuse)
Tissue: ,,fat, ,,bone, ,,blood/brain ,,barrier ,,(only ,,lipid ,,soluble ,,will ,,pass), ,,placental ,,barrier ,,(many ,,drugs ,,can
,,pass)
Protein ,,binding ,,- ,,ANSWER: ,, ,,➡ ,,unbound ,,drug ,,is ,,free ,,which ,,is ,,active, ,,crosses ,,membrane. ,,Low ,,plasma
,,proteins ,,result ,,in ,,more ,,free ,,drug. ,,Competition: ,,when ,,2 ,,highly ,,bound ,,drugs ,,are ,,given ,,it ,,increases ,,the
,,level ,,of ,,both ,,drugs
Metabolism ,,- ,,ANSWER: ,, ,,➡ ,,take ,,place ,,in ,,the ,,liver ,,mostly. ,,Chemical ,,change ,,of ,,a ,,drug ,,structure ,,to: ,,
Enhance ,,excretion, ,,inactivate ,,the ,,drug, ,,increase ,,therapeutic ,,action, ,,active ,,a ,,prodrug ,,(inactive ,,until
,,metabolized ,,in ,,the ,,body ,,into ,,the ,,active ,,compound, ,,ex: ,,levodopa), ,,increase ,,or ,,decrease ,,toxicity
CYP450 ,,- ,,ANSWER: ,, ,,➡ ,,enzymes ,,constitutes ,,the ,,most ,,important ,,of ,,the ,,phase ,,I ,,metabolizing ,,enzymes
,,(account ,,for ,,about ,,75% ,,of ,,drug ,,metabolism ,,in ,,the ,,liver)
Phase ,,2: ,,conjugation ,,reaction ,,occur ,,leading ,,to ,,large ,,increases ,,in ,,hydrophilicity ,,of ,,the ,,substrates
,,rendering ,,them ,,more ,,readily ,,excretable
Substrate ,,- ,,ANSWER: ,, ,,➡ ,,an ,,agent ,,that ,,is ,,metabolized ,,by ,,an ,,enzyme ,,into ,,a ,,metabolite ,,and ,,product
,,and ,,eventually ,,excreted
,Inhibitors ,,- ,,ANSWER: ,, ,,➡ ,,compete ,,with ,,other ,,drugs ,,for ,,a ,,particular ,,enzyme ,,affecting ,,the ,,metabolism
,,(decreased) ,,of ,,the ,,substrate ,,and ,,decreases ,,the ,,excretion ,,of ,,the ,,substrate ,,and ,,increasing ,,the
,,circulating ,,drug
inducer ,,- ,,ANSWER: ,, ,,➡ ,,competes ,,with ,,other ,,drugs ,,for ,,a ,,particular ,,enzyme ,,affecting ,,metabolism ,,of
,,the ,,substrate ,,(increases) ,,decreasing ,,the ,,efficacy ,,of ,,the ,,drug
excretion ,,- ,,ANSWER: ,, ,,➡ ,,renal: ,,passive ,,glomerular ,,filtration, ,,active ,,tubular ,,secretion, ,,tubular
,,reabsorption, ,,gi ,,tract, ,,lung, ,,sweat ,,and ,,salivary, ,,mammary
genomics ,,- ,,ANSWER: ,, ,,➡ ,,study ,,of ,,the ,,complete ,,set ,,of ,,genetic ,,information ,,present ,,in ,,a ,,cell, ,,an
,,organism, ,,or ,,species
pharmacogenetics ,,- ,,ANSWER: ,, ,,➡ ,,the ,,study ,,of ,,the ,,influence ,,of ,,hereditary ,,factors ,,on ,,the ,,response ,,of
,,individual ,,organisms ,,to ,,drugs, ,,and ,,the ,,study ,,of ,,variations ,,of ,,DNA ,,and ,,RNA ,,characteristics ,,as ,,related
,,to ,,drug ,,response
Pharmacogenetics ,,tests ,,- ,,ANSWER: ,, ,,➡ ,,Mentioned ,,on ,,drug ,,labels ,,can ,,be ,,classified ,,as ,,"test ,,required,"
,,"test ,,recommended," ,,and ,,"information ,,only." ,,Currently, ,,four ,,drugs ,,are ,,required ,,to ,,have
,,pharmacogenetics ,,testing ,,performed ,,before ,,they ,,are ,,prescribed: ,,cetuximab, ,,trastuzumab, ,,maraviroc
,,and ,,dasatinib
wafarin, ,,carbamazepine, ,,valproic ,,acid ,,and ,,abacavir ,,are ,,recommended ,,to ,,tests ,,prior ,,to ,,initial ,,dosing
Carbamazepine ,,and ,,Asisans ,,- ,,ANSWER: ,, ,,➡ ,,Initiating ,,carbamazepine ,,therapy ,,in ,,these ,,patients ,,(allele
,,HLA-B*1502) ,,are ,,at ,,high ,,risk ,,for ,,developing ,,Steven ,,Johnson ,,syndrome ,,or ,,toxic ,,epidermal ,,necrolysis
,,(TEN)
The ,,ability ,,of ,,the ,,anesthetic ,,to ,,penetrate ,,the ,,axon ,,membrane ,,is ,,determined ,,by ,,3 ,,properties. ,,What
,,are ,,they? ,,- ,,ANSWER: ,, ,,➡ ,,Molecular ,,size, ,,Lipid ,,solubility, ,,degree ,,of ,,ionization ,,at ,,tissue ,,pH
Why ,,is ,,epinephrine ,,given ,,with ,,local ,,anesthetics? ,,- ,,ANSWER: ,, ,,➡ ,,Decreases ,,local ,,blood ,,flow
,,(decreased ,,risk ,,of ,,bleeding)
, Delays ,,systemic ,,absorption ,,of ,,the ,,anesthetic
prolongs ,,anesthesia
reduces ,,the ,,risk ,,of ,,toxicity
What ,,is ,,the ,,most ,,widely ,,used ,,local ,,anesthetic? ,,- ,,ANSWER: ,, ,,➡ ,,Lidocaine
What ,,is ,,a ,,possible ,,fatal ,,reaction ,,to ,,benzocaine ,,- ,,ANSWER: ,, ,,➡ ,,Methemoglobinemia
What ,,is ,,included ,,in ,,application ,,guidelines ,,for ,,topical ,,anesthetics ,,- ,,ANSWER: ,, ,,➡ ,,avoid ,,wrapping ,,the
,,site ,,and ,,heating ,,the ,,site, ,,avoid ,,application ,,to ,,open ,,skin
Which ,,medication ,,will ,,not ,,cause ,,rebound ,,headaches ,,from ,,overuse? ,,- ,,ANSWER: ,, ,,➡ ,,propranolol
,,(preventative)
What ,,is ,,the ,,best ,,option ,,for ,,menstural ,,migraine? ,,- ,,ANSWER: ,, ,,➡ ,,low ,,dose ,,estrogen ,,about ,,3 ,,days
,,prior ,,to ,,menses
What ,,food ,,can ,,trigger ,,migraines? ,,- ,,ANSWER: ,, ,,➡ ,,Hot ,,dog ,,d/t ,,nitrates
What ,,medication ,,is ,,a ,,Seratonin ,,1B1D ,,receptor ,,agonist? ,,- ,,ANSWER: ,, ,,➡ ,,Sumatriptan
Butterbur ,,can ,,help ,,as ,,prevention ,,for ,,migraine ,,therapy. ,,What ,,side ,,effect ,,can ,,occur? ,,- ,,ANSWER: ,, ,,➡
,,Liver ,,damage
What ,,are ,,the ,,3 ,,main ,,classes ,,of ,,opiod ,,receptors? ,,- ,,ANSWER: ,, ,,➡ ,,Mu ,,kappa ,,delta
Which ,,of ,,the ,,following ,,will ,,reserve ,,he ,,effects ,,caused ,,by ,,opioid ,,agonist? ,,- ,,ANSWER: ,, ,,➡ ,,naloxone
Which ,,of ,,the ,,medications ,,are ,,used ,,to ,,treat ,,OIC? ,,- ,,ANSWER: ,, ,,➡ ,,Naloxegol, ,,methylinaltrexone,
,,lubiprostone